Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P-H Groop

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
Pharmacogenetics|December 11, 1999
N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathyE Korpinen, P H Groop, A Rautio, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 11, 2012
INPPL1 is associated with the metabolic syndrome in men with Type 1 diabetes, but not with diabetic nephropathyM E Hyvönen, P Ihalmo, C Forsblom, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 17, 2001
Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with Type 1 diabetes mellitus with diabetic nephropathyE Korpinen, P H Groop, J A Fagerudd, et al.
Nordisk Medicin|May 1, 1997
[Diabetic nephropathy--screening, follow-up and treatment. Nephropathy Study Groups of The Finnish Diabetes Organization]V Koivisto, P H Groop, N P Huttunen, et al.
Kidney International|September 6, 2000
Albuminuria in nondiabetic relatives of IDDM patients with and without diabetic nephropathyJ A Fagerudd, K J Pettersson-Fernholm, M K Riska, et al.
Clinical Pharmacology and Therapeutics|August 13, 2013
Metabolic phenotyping of diabetic nephropathyV-P Mäkinen, A J Kangas, P Soininen, et al.
Diabetologia|July 1, 1993
Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitusL Groop, A Ekstrand, C Forsblom, et al.
Diabetes Care|November 1, 1987
Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatmentL Groop, P H Groop, S Stenman, et al.
Diabetologia|August 18, 2012
HLA class II is a factor in cardiovascular morbidity and mortality rates in patients with type 1 diabetesJ Söderlund, C Forsblom, J Ilonen, et al.
Diabetes|November 1, 1987
Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjectsL Groop, L Luzi, A Melander, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
Pharmacogenetics|December 11, 1999
N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathyE Korpinen, P H Groop, A Rautio, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 11, 2012
INPPL1 is associated with the metabolic syndrome in men with Type 1 diabetes, but not with diabetic nephropathyM E Hyvönen, P Ihalmo, C Forsblom, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 17, 2001
Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with Type 1 diabetes mellitus with diabetic nephropathyE Korpinen, P H Groop, J A Fagerudd, et al.
Nordisk Medicin|May 1, 1997
[Diabetic nephropathy--screening, follow-up and treatment. Nephropathy Study Groups of The Finnish Diabetes Organization]V Koivisto, P H Groop, N P Huttunen, et al.
Kidney International|September 6, 2000
Albuminuria in nondiabetic relatives of IDDM patients with and without diabetic nephropathyJ A Fagerudd, K J Pettersson-Fernholm, M K Riska, et al.
Clinical Pharmacology and Therapeutics|August 13, 2013
Metabolic phenotyping of diabetic nephropathyV-P Mäkinen, A J Kangas, P Soininen, et al.
Diabetologia|July 1, 1993
Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitusL Groop, A Ekstrand, C Forsblom, et al.
Diabetes Care|November 1, 1987
Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatmentL Groop, P H Groop, S Stenman, et al.
Diabetologia|August 18, 2012
HLA class II is a factor in cardiovascular morbidity and mortality rates in patients with type 1 diabetesJ Söderlund, C Forsblom, J Ilonen, et al.
Diabetes|November 1, 1987
Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjectsL Groop, L Luzi, A Melander, et al.
Pageof 14